Zacks Investment Research
18 May 2026, 15:50 UTC · 19w ago
Verdict
Headline leans bullish. We score NTRA +0.60 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
More positive than 76% of ticker scores this week
Search tags
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA approved Natera's Signatera CDx as a companion diagnostic for use with atezolizumab in patients with muscle-invasive bladder cancer.
More positive than 93% of claims this week
Natera (NTRA) shares decreased by 5.4% following the announcement of the FDA approval.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 78% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company received FDA approval for Signatera CDx, marking a major milestone in personalized oncology, despite a recent short-term share price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
9h ago
+120.2%
Price agrees with the score
$410.35 vs $186.36 close before publication (May 15) · not market-adjusted
NTRA chart →
